Saw Palmetto

  • Timothy S. Tracy
Part of the Forensic Science and Medicine book series (FSM)


Administration of saw palmetto can be effective in treating symptoms of benign prostatic hyperplasia, and its use may have benefit in stimulating hair growth. Adverse effects of saw palmetto therapy are usually mild and its use does not appear to result in significant drug interactions.

Key Words

Serenoa repens BPH prostate health antiandrogens 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chavez ML. Saw palmetto. Hosp Pharm 1998;33:1335–1361.Google Scholar
  2. 2.
    Nemecz G. Saw palmetto. US Pharm 1998;23:97–98, 100-102.Google Scholar
  3. 3.
    Tyler VE, ed. The Honest Herbal, 3rd edition, Binghamton: Pharmaceutical Products Press, 1993.Google Scholar
  4. 4.
    Anonymous. Saw palmetto. In: The Lawrence Review of Natural Products. St. Louis: Facts and Comparisons, 1994.Google Scholar
  5. 5.
    United States Pharmacopoeia. National Formulary, 18th edition, Supplement 9, Rockville: United States Pharmacopeial Convention, 1998.Google Scholar
  6. 6.
    Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia. JAMA 1998;280:1604–1609.PubMedCrossRefGoogle Scholar
  7. 7.
    Briley M, Carilla E, Fauran F. Permixon, a new treatment for benign prostatic hyperplasia, acts directly at the cytosolic androgen receptor in rat prostate [abstract]. Br J Pharmacol 1983;79:327P.Google Scholar
  8. 8.
    Sultan C, Terraza A, Devillier C, et al. Inhibition of androgen metabolism and binding by a liposterolic extract of “Serenoa repens B” in human foreskin fibroblasts. J Steroid Biochem 1984;20:515–519.PubMedCrossRefGoogle Scholar
  9. 9.
    Habib FK, Ross M, Ho CKH, Lyons V, Chapman K. Serenoa repens (Permixon®) inhibits the 5a-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 2005;114:190–194.PubMedCrossRefGoogle Scholar
  10. 10.
    Goepel M, Dinh L, Mitchell A, Schafers RF, Rubben H, Michel MC. Do saw palmetto extracts block human al-adrenoceptor subtypes in vivo? Prostrate 2001;46:226–232.CrossRefGoogle Scholar
  11. 11.
    Talpur N, Echard B, Bagchi D, Bagchi M, Preuss HG. Comparison of saw palmetto (extract and whole berry) and cernitin on prostate growth in rats. Mol Cell Biochem 2003;250:21–26.PubMedCrossRefGoogle Scholar
  12. 12.
    Breu W, Hagenlocher M, Redl K, Tittel G, Stadler F, Wagner H. Antiphlogistic activity of an extract from Sabal serrulata fruits prepared with supercritical carbon dioxide. In-vitro inhibition of cyclooxygenase and 5-lipoxygenase metabolism. Arzneim Forsch 1992;42:547–551.Google Scholar
  13. 13.
    Blumenthal M, Riggins CW. Saw palmetto berry. In: Popular Herbs in the US Market. Therapeutic Monographs. Austin: American Botanical Council, 1997.Google Scholar
  14. 14.
    Di Silverio F, D’Eramo G, Lubrano C, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992;21:309–314.PubMedGoogle Scholar
  15. 15.
    Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984; 18:461–462..PubMedGoogle Scholar
  16. 16.
    Carraro J, Raynaud J, Koch G, et al. Comparison of phy to therapy (Permixon®) with finasteride in the treatment of benign prostatic hyperplasia; a randomized international study of 1,098 patients. Prostate 1996;29:231–240.PubMedCrossRefGoogle Scholar
  17. 17.
    Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5alphareductase types I and II inhibitor — new evidence in a coculture model of BPH. Prostate 1999;40:232–241.PubMedCrossRefGoogle Scholar
  18. 18.
    Gerber GS, Kusnetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw pollmetto in men with lower urinary tract symptoms. Urology 2001;58:960–965.PubMedCrossRefGoogle Scholar
  19. 19.
    Marks LS, Partin AW, Epstein JI, et al. Effects of saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000;163:1451–1456.PubMedCrossRefGoogle Scholar
  20. 20.
    Veltri RW, Marks LS, Miller MC, et al. Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. Urology 2002;60:617–622.PubMedCrossRefGoogle Scholar
  21. 21.
    Preuss HG, Marcusen C, Regan J, Klimberg IW, Welebir TA, Jones WA. Randomized trial of a combination of natural products (cernitin, saw palmetto, β-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). Int Urol Nephrol 2001;33:217–225.PubMedCrossRefGoogle Scholar
  22. 22.
    Kaplan S A, Volpe MA, Te AE. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol 2004;171:284–288.PubMedCrossRefGoogle Scholar
  23. 23.
    Al-Shukri SH, Deschaseaux P, Kuzmin IV, Amdiy RR. Early urodynamic effects of the lipido-sterolic extract of Serenoa repens (Permixon®) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2000;3:195–199.PubMedCrossRefGoogle Scholar
  24. 24.
    Pytel YA, Vinarov A, Lopatkin N, Sivkov A, Gorilovsky L, Raynaud JP. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv Natural Ther 2002; 19:297–306.Google Scholar
  25. 25.
    Prager N, Bickett K, French N, Marcovici G. J Altern Complement Med 2002;8: 143–152.PubMedCrossRefGoogle Scholar
  26. 26.
    Zlotta AR, Teillac P, Raynaud JP, Schulman CC. Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hypertrophy (BPH) treated with a phytotherapeutic agent (Permixon®), tamsulosin or finasteride. Eur Urol 2005;48:269–276.PubMedCrossRefGoogle Scholar
  27. 27.
    Hamid S, Rojter S, Vierling J. Protracted cholestatic hepatitis after the use of Prostata. Ann Intern Med 1997; 127:169–179.PubMedGoogle Scholar
  28. 28.
    Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of saw palmetto herb: a case report and review of literature. J Intern Med 2001;250:167–169.PubMedCrossRefGoogle Scholar
  29. 29.
    Plosker GL, Brogden RN. Serenoa repens (Permixon®). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drug Aging 1996;9:379–395.CrossRefGoogle Scholar
  30. 30.
    De Bernardi di Valserra M, Tripodi AS. Rectal bioavailability and pharmacokinetics of Serenoa repens new formulation in healthy volunteers. Arch Med Intern 1994;46:77–86.Google Scholar
  31. 31.
    De Bernardi Di Valerra M, Tripodi AS, Contos S, Germogli R. Serenoa repens capsules: a bioequivalence study. Acta Toxicol Ther 1994; 15:21–39.Google Scholar
  32. 32.
    Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens of the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Comp Med 2005; 11:433–439.CrossRefGoogle Scholar
  33. 33.
    Markowitz JS, Donovan JL, DeVane CL, et al. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 2003;74:536–542.PubMedCrossRefGoogle Scholar
  34. 34.
    Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantum, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004;76:428–440.PubMedCrossRefGoogle Scholar
  35. 35.
    Blumenthal M. Therapeutic guide to herbal medicine. In: The Complete German Commission E Monographs. Austin: American Botanical Council, 1998.Google Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Timothy S. Tracy

There are no affiliations available

Personalised recommendations